Signalling pathways and involved entities that are unravelling experimental therapeutic targets for TNBC. Depicted molecular landscape of TNBC confers.

Slides:

Advertisements

Similar presentations

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non- small cell lung cancer: Focus on epidermal growth factor receptor.

Advertisements

Silvestri Gerard A. , MD, FCCP, Rivera M. Patricia , MD, FCCP CHEST

Figure 1. Resistance mechanism against first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). (A) Mutations in the EGFR.

Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors Sara Charmsaz, Andrew M. Scott,

Targeting signal transduction

Targeting the DNA Damage Response in Cancer

Targeting the PARP DNA repair pathway enhanced cytotoxicity induced by chemotherapy. Targeting the PARP DNA repair pathway enhanced cytotoxicity induced.

Akihito Muto, MD, PhD, Tamara N. Fitzgerald, MD, PhD, Jose M

Figure 1 CTLA-4 and PD-1–PD-L1 immune checkpoints

Figure 2 Crosstalk between TGF-β/Smad and other pathways in tissue fibrosis Figure 2 | Crosstalk between TGF-β/Smad and other pathways in tissue fibrosis.

(A) Programmed cell death ligand-1 (PD-L1) expression score was significantly higher in pulmonary adenocarcinomas with grade G2/G3 differentiation as compared.

Volume 71, Issue 2, Pages (February 2017)

Sustaining Proliferative Signaling and Evading Growth Suppressors

Immunologic pathomechanism of Hodgkin's lymphoma

Mechanisms mediating the clinical activities of anti-PD-1/PD-L1/CTLA-4 antibodies. Mechanisms mediating the clinical activities of anti-PD-1/PD-L1/CTLA-4.

Figure 2 Signalling pathways and physiological domains that are

Miriam Marqués, Francisco X. Real European Urology

Nitin TELANG 1, Hareesh B NAIR 2, George YC WONG 3, 4

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart summarising the process for the identification of eligible studies.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 4 Possible combination therapies CDK4/6 inhibitors

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Latest Advances in Chemotherapeutic, Targeted, and Immune Approaches in the Treatment of Metastatic Melanoma Darshil J. Shah, MD, MPH, Roxana S. Dronca,

Figure 1 A schematic representation of the HER2 signalling pathway

Volume 56, Issue 3, Pages (March 2012)

Nat. Rev. Urol. doi: /nrurol

Axl Receptor Axis: A New Therapeutic Target in Lung Cancer

Immunohistochemistry of CD8 (A and B) and PD-L1 (C–F).

Schematic representation of main EGFR-TKIs resistance mechanisms.

Chapter 3 Treatment guidelines for NSCLC that does not have targetable driver mutations.

Schematic view of Trk receptors signalling, showing the three major pathways involved in cell differentiation and survival. Schematic view of Trk receptors.

Figure 5 The mechanism underlying epithelial-to-mesenchymal

A model for the biological rationale for rechallenge therapy: clonal selection in heterogeneous baseline RAS a wt tumours during anti-EGFR therapy. aAdditional.

Keratinocyte Apoptosis in Epidermal Development and Disease

Progesterone receptor nuclear morphology patterns in breast cancer.

Nat. Rev. Urol. doi: /nrurol

Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors Sara Charmsaz, Andrew M. Scott,

BRAF Alterations as Therapeutic Targets in Non–Small-Cell Lung Cancer

Detection rate for EGFR mutations in cfDNA.

Mechanism of CTLA-4-induced immunosuppression.

Nat. Rev. Endocrinol. doi: /nrendo

Histological and molecular heterogeneity of triple negative breast cancer (TNBC). Histological and molecular heterogeneity of triple negative breast cancer (TNBC).

Clinical courses of patients.

Volume 73, Issue 1, Pages 5-7 (January 2008)

Vascular Endothelial Growth Factor and Epidermal Growth Factor Signaling Pathways as Therapeutic Targets for Colorectal Cancer Thomas Winder, Heinz–Josef.

Detection rate of EGFR mutations in cfDNA by characteristics

(A) Survival time. (A) Survival time. All patients. (a) PFS since the start of EGFR-TKI (groups A, B and C). (b) OS since the start of EGFR-TKI (groups.

Programmed cell death ligand-1 (PD-L1) immunohistochemistry for pulmonary adenocarcinoma tissues. Programmed cell death ligand-1 (PD-L1) immunohistochemistry.

PFS by dose of nivolumab for (A) all patients (n=47), (B) PD-L1-positive patients (n=13) and (C) PD-L1-negative or unknown patients (n=34). mPFS, median.

Newly Discovered Olfactory Receptors in Epidermal Keratinocytes Are Associated with Proliferation, Migration, and Re-Epithelialization of Keratinocytes

Kaplan-Meier curves of OS by dose of nivolumab for (A) all patients (n=47), (B) PD-L1-positive patients (n=13) and (C) PD-L1-negative or unknown patients.

Summary of this study. Summary of this study. Cysteinyl-leukotrienes (cys-LTs) stimulate mitogenesis of bronchial fibroblasts only in the presence of RTK.

Simon Ekman, MD, PhD, Murry W. Wynes, PhD, Fred R. Hirsch, MD, PhD

Platelet-derived growth factor (PDGF) signalling pathway.

(A) Progression-free survival in the hormone receptor-negative cohort patients treated with PARPi versus those treated with mono chemotherapy (controls).

Jinhua Tang, Na Liu, Shougang Zhuang Kidney International

Objective response rate in patients with BRCA-mutated HER2-negative breast cancer treated with PARPi versus those treated with monochemotherapy (controls).

Mechanism of PD-1/PD-L1 pathway-induced immunosuppression within the tumour microenvironment. Mechanism of PD-1/PD-L1 pathway-induced immunosuppression.

The mitogen-activated protein kinase (MAPK) pathway showing mutations identified in pulmonary Langerhans cell histiocytosis (PLCH). The mitogen-activated.

Distribution of immune checkpoint in tumor cells and immune microenvironment. CTLA-4, cytotoxic T lymphocyte antigen-4; MHC, major histocompatibility complex;

(A) Progression-free survival in patients with BRCA-mutated HER2-negative breast cancer treated with PARPi versus those treated with monochemotherapy (controls).

Overview of important signalling pathways in angiogenesis and antiangiogenic agents. Overview of important signalling pathways in angiogenesis and antiangiogenic.

Treatmentalgorithm for metastatic TNBC patients consideringthe incorporation of PARPis and immunotherapy. *Defined as PD-L1 expression on tumour-infiltratingimmune.

Heterogeneity in the natural history of triple negative breast cancer.

(A) Lymph node priming phase: recognition of major histocompatibility complex (MHC) by T-cell receptor (TCR), coactivating CD 28/B7 pathway activation.

Human cancer immunotherapy strategies targeting B7-H3 A, blockade of B7-H3 with blocking mAbs neutralizes inhibitory signaling in its unidentified receptor(s)

Schematic representation of signaling pathways associated with cannabinoid receptor activation induced by its agonists. Schematic representation of signaling.

Regulation of signaling by wild-type and oncogenic Ras.

Patterns of clinical relapse and algorithm for the therapeutic strategy when AR to EGFR TKI occurs in patients with EGFR-mutant NSCLC. *After discussion.

Four classes of agents that can be used to treat multiple myeloma.

Presentation transcript:

Signalling pathways and involved entities that are unravelling experimental therapeutic targets for TNBC. Depicted molecular landscape of TNBC confers an insight of novel and investigational targeted therapeutic strategy which are directly unlocking its heterogeneous biology. Signalling pathways and involved entities that are unravelling experimental therapeutic targets for TNBC. Depicted molecular landscape of TNBC confers an insight of novel and investigational targeted therapeutic strategy which are directly unlocking its heterogeneous biology. In the context of its intrinsic genetic instability which derives an immunogenic microenvironment, blockade of the immune-checkpoint targeting PD-1 and PD-L1 as well as CTLA-4 can boost the adaptive immune reaction. PAM signalling pathways are actively participating in cell cycle regulation, which are in the tight network with various growth factors including EGF and MAPK signalling. Platinum-based agents and PARPi is a master regulator of DNA damage repair and can induce synergistic inhibitory effect in TNBC harbouring BRCAness. Other multikinase inhibitors involving angiogenesis or developmental process are also a potential therapeutic entity of current interest. All these investigational but key targets are consistently interacting with cytotoxic effect of conventional chemotherapy. CTLA-4, cytotoxic T-lymphocyte-associated protein 4; EGF, epidermal growth factor; EGFR, EGF receptor; ERK, extracellular signal-related kinase; MAPK, mitogen-activated protein kinase; MEK, MAPK kinase; PAM, PI3K-Akt-mTOR; PARP, poly(ADP-ribose) polymerase; PARPi, PARP inhibitors; PD-1, programmed cell death protein 1; PD-L1, programmed cell death ligand 1; TNBC, triple-negative breast cancer. Ji Hyun Park et al. ESMO Open 2018;3:e000357 Copyright © European Society for Medical Oncology. All rights reserved.